Mesoblast Limited (MESO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Mesoblast Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Mesoblast Limited (MESO) has returned -14.75% so far this year and 23.24% over the past 12 months. Over the last ten years, MESO has returned -2.14% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Nov 13, 2015, MESO's average daily return is +0.16%, while the average monthly return is +3.20%. At this rate, your investment would double in approximately 1.8 years.

Historically, 47% of months were positive and 53% were negative. The best month was Apr 2020 with a return of +154.3%, while the worst month was Aug 2023 at -59.8%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.

On a daily basis, MESO closed higher 46% of trading days. The best single day was Apr 24, 2020 with a return of +139.5%, while the worst single day was Aug 4, 2023 at -58.9%.

Mesoblast Limited has an annualized alpha of 25.31%, beta of 1.39, and R² of 0.07 versus S&P 500 Index. Calculated based on daily prices since November 16, 2015.

• This stock participated in 173.21% of S&P 500 Index downside but only 132.48% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.07 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

MESO ranks 55 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Mesoblast Limited (MESO) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Mesoblast Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Mesoblast Limited was 95.66%, occurring on Jan 18, 2024. The portfolio has not yet recovered.

The current Mesoblast Limited drawdown is 61.18%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Mesoblast Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Mesoblast Limited is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.